Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZ6089 |
Synonyms | |
Therapy Description |
AZ6089 (AZ12576089) binds and inhibits FGFR1, 2, 3, and 4, which may result in the inhibition of FGFR mediated signal transduction pathways and inhibition of tumor cell proliferation (PMID: 22869148). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZ6089 | AZ12576089 | FGFR Inhibitor (Pan) 26 | AZ6089 (AZ12576089) binds and inhibits FGFR1, 2, 3, and 4, which may result in the inhibition of FGFR mediated signal transduction pathways and inhibition of tumor cell proliferation (PMID: 22869148). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 wild-type | Advanced Solid Tumor | predicted - sensitive | AZ6089 | Preclinical | Actionable | In a preclinical study, AZ12576089 (AZ6089) inhibited FGF2-induced ERK1/2 phosphorylation and cell proliferation in transformed fibroblasts in culture (PMID: 22869148). | 22869148 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|